<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00459004</url>
  </required_header>
  <id_info>
    <org_study_id>DRI5747</org_study_id>
    <nct_id>NCT00459004</nct_id>
  </id_info>
  <brief_title>Japanese Dose-Response Study of Rimonabant in Obese Patients</brief_title>
  <official_title>A Dose-Response Relationship Study of SR141716 in Obese Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      The primary objective is to verify the dose-response relationship of rimonabant on body
      weight change.

      The secondary objectives are to compare the effect of 3 doses of SR141716 to placebo, on body
      weight loss and on secondary criteria associated with comorbidities, and to evaluate the
      safety and the pharmacokinetics of SR141716.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <completion_date type="Actual">April 2006</completion_date>
  <primary_completion_date type="Actual">April 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>absolute change in body weight from baseline to Week 24</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy: body weight, visceral fat area, waist circumference, fasting plasma glucose, HbA1c, triglyceride, HDL-cholesterol, blood pressure</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety:adverse events, laboratory tests, ECGs</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: SR141716 plasma trough concentrations</measure>
  </secondary_outcome>
  <enrollment type="Actual">527</enrollment>
  <condition>Obesity</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rimonabant (SR141716)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body Mass Index ≥25 kg/m²

          -  Viceral Fat Area ≥ 100 cm²

          -  Diet therapy for more than 8 weeks before start of the placebo observation period

          -  Stable weight (variation &lt; ±3kg within 8 weeks before start of observation period)

          -  At least 2 criteria of the following 3 comorbidities: Impaired Glucose Tolerance or
             Type 2 diabetes, Dyslipidemia (hypertriglyceridemia and/or low HDL-choresterol),
             Hypertension
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kohji SHIRAI, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Toho University Sakura Medical Center, Japan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 10, 2007</study_first_submitted>
  <study_first_submitted_qc>April 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2007</study_first_posted>
  <last_update_submitted>April 6, 2009</last_update_submitted>
  <last_update_submitted_qc>April 6, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 7, 2009</last_update_posted>
  <responsible_party>
    <name_title>ICD Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <keyword>weight loss</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rimonabant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

